hereditary disease
Revvity, Element Biosciences to Collaborate on Newborn Sequencing Workflow
Revvity separately said that it expects Q4 2024 revenue growth of 5 percent, or 6 percent organically, year over year.
GeneDx Stock Soars as Firm Reports 44 Percent Revenue Growth, $1.2M Adjusted Net Income in Q3
Premium
Revenues in the third quarter were driven by diagnostic exome and genome tests, which grew 76 percent in revenue and 46 percent in volume, prompting the firm to raise its 2024 guidance.
ESHG: Short-Read Genome Sequencing Boosts Rare Disease Diagnoses in European Solve-RD Project
Premium
So far, 90 out of 836 or about 10 percent of families who were analyzed by short-read genome sequencing as part of Solve-RD have received a diagnosis.
NHS England Unveils Five-Year Genomic Healthcare Strategy
The new strategy places genomics at the heart of a new effort to deliver a sustainable model of healthcare for patients.
At the inaugural International Conference on Newborn Sequencing (ICoNS) in Boston last week, researchers outlined plans from eight studies in the US, the UK, Europe, and Australia.